Bevacizumab, a recombinant monoclonal antibody targeting vascular endothelial growth factor (VEGF), which plays a role in angiogenesis, is used in the treatment of ovarian and cervical cancer (Yetkin-Arik et al., 2021). Here, VEGFA is linked to cervical carcinoma.